Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented mixed signals: while product development with GenesisX and new catheters is promising, financials show consistent losses and a negative cash flow. The Q&A reveals a cautious approach to new launches and regulatory approvals, indicating uncertainty. No strong catalysts like partnerships or guidance changes were mentioned. Therefore, the stock is likely to remain stable in the short term.
Key Financial Performance
Revenue for Q3 2025 $7.5 million, a decrease from $9.2 million in the prior year third quarter. The decline was due to lower system revenue, partially offset by growth in recurring revenue.
System Revenue for Q3 2025 $1.9 million, compared to $4.4 million in the prior year third quarter. The decrease reflects partial revenue recognition on 1 Genesis system and ancillary devices.
Recurring Revenue for Q3 2025 $5.6 million, compared to $4.8 million in the prior year third quarter. The increase reflects a full quarter's contribution of Map-iT catheters and initial sales of new robotically navigated devices.
Gross Margin for Q3 2025 55% of revenue. Recurring revenue gross margin was 67%, and system gross margin was 19%. Gross margins remain impacted by fixed overhead allocated over low production levels.
Operating Expenses for Q3 2025 $10.7 million, including $4.1 million in noncash charges. Adjusted operating expenses were $6.6 million, a decrease from $7.2 million in the prior year third quarter due to lower general and administrative expenses.
Operating Loss for Q3 2025 $6.6 million, compared to $6.3 million in the prior year third quarter. Adjusted operating loss was $2.5 million, compared to $3.1 million in the prior year third quarter.
Net Loss for Q3 2025 $6.5 million, compared to $6.2 million in the prior year third quarter. Adjusted net loss was $2.4 million, compared to $3 million in the prior year third quarter.
Negative Free Cash Flow for Q3 2025 $4.2 million, consistent with the previous year.
Cash and Cash Equivalents as of September 30, 2025 $10.5 million, with no debt. Including $4 million from the upcoming second closing of registered direct financing, cash would have been $14.5 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
GenesisX System: Received FDA approval, marking a significant milestone for Stereotaxis. Limited launch initiated, with expectations for full launch after refining supply chain and manufacturing processes.
MAGiC Sweep Catheter: First catheter launch in the U.S., generating $300,000 in revenue within the first two months. Allows for better diagnosis of arrhythmias and enables new clinical applications.
Synchrony and SynX Digital Cath Lab System: Obtained CE Mark in Europe and submitted for FDA approval. Expected to generate a couple of million dollars in revenue in the first year of launch.
European Market Expansion: Two Genesis robots ordered by European hospitals, reflecting strong interest and a more complete product ecosystem in the region.
MAGiC Sweep Catheter in Europe: Plans to gain approval and launch in Europe, following its successful U.S. launch.
Recurring Revenue Growth: Recurring revenue grew to $5.6 million in Q3 2025, driven by new catheter sales and service contracts.
Gross Margin: Gross margin for Q3 2025 was 55%, with recurring revenue gross margin at 67%.
Razor-Razorblade Business Model: Focus on scaling robotic system sales and building a high-margin recurring revenue business with novel catheters.
PFA Collaboration with CardioFocus: Entered into a collaboration to integrate CardioFocus' PFA system with the MAGiC catheter, aiming for first-in-human testing and potential European approval by the end of 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Delays: The company is awaiting FDA approval for the MAGiC catheter in the U.S., which could delay the full launch of GenesisX and impact revenue growth.
Supply Chain and Manufacturing Challenges: The company is refining its supply chain and manufacturing processes for GenesisX, which could pose risks to timely production and delivery.
Limited Adoption of New Products: MAGiC Sweep catheter has only been adopted by about 25% of robotic accounts in the U.S., indicating potential challenges in scaling adoption.
Financial Losses and Cash Flow: The company reported an operating loss of $6.6 million and negative free cash flow of $4.2 million for the quarter, which could impact its ability to fund future operations and innovations.
Market Competition: The electrophysiology field is experiencing significant market growth and share shifts among large med-tech players, posing competitive pressures on Stereotaxis.
Economic Dependency on Recurring Revenue: The company’s recurring revenue is heavily reliant on the adoption of its proprietary catheters, which could be a risk if adoption rates do not meet expectations.
Technological and Product Development Risks: The company is investing in multiple late-stage and early-stage innovation projects, which may not all succeed or generate expected returns.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Revenue for the fourth quarter of 2025 is expected to exceed $9 million, with system revenue of approximately $3 million and recurring revenue greater than $6 million. This will result in over 20% annual revenue growth for the full year 2025. Quarterly revenue is expected to surpass an average of $10 million per quarter in 2026.
Product Launches and Market Trends: The GenesisX system has received FDA approval, and a limited launch is underway. Full launch is expected after enhancements to compatibility, supply chain, and commercial processes. GenesisX orders are anticipated to outpace Genesis orders post-launch. The MAGiC Sweep catheter has shown strong initial adoption in the U.S., with plans for European approval and launch. The MAGiC catheter is expected to gain U.S. FDA approval soon, with potential for PFA use in Europe by the end of 2026. Synchrony and SynX digital solutions are expected to contribute a couple of million dollars in revenue in their first year of launch, with potential for a growing SaaS revenue stream.
Growth Expectations: Sustained growth in both systems and recurring revenue is expected through 2026, driven by the GenesisX launch and increased adoption of MAGiC, MAGiC Sweep, and Map-iT catheters. The company anticipates achieving profitability with improved margins and earnings accretion.
Capital Expenditures and Financial Position: The company expects to enter 2026 with a healthy balance sheet, enabling the advancement and launch of new technologies while maintaining a focus on growth and profitability.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the sales pipeline update for GenesisX, especially in Europe and the U.S.?
A:GenesisX is seen as additive to Genesis, with demand for Genesis continuing at a pace of 1-2 systems per quarter in both the U.S. and Europe. GenesisX offers access to robotics for physicians who faced logistical challenges at hospitals. The company is ramping up manufacturing and plans to open up leasing and placement models with disposable commitments. A full launch is expected to result in a higher rate of orders for GenesisX.
Q:Will GenesisX be sold at a similar price point to Genesis or at a premium?
A:GenesisX is priced at a premium to Genesis, as it is a new technology and a premium system. The market is accepting of this pricing.
Q:When will non-EP centers start using GenesisX, and what is the status of guide catheter and guidewire approvals?
A:At least 1-2 non-EP centers are expected to start using GenesisX next year. The guide catheter submission is under regulatory review, and the guidewire submission is expected early next year. Initial use of these devices will likely be in existing robotic accounts, with some adoption in non-EP centers.
Q:When will the U.S. approval of GenesisX transition from a limited launch to a full launch?
A:The transition to a full launch is expected in the earlier parts of next year, potentially around the spring conferences (ERA and HRS). This depends on MAGiC RF approval in the U.S. and ramping up manufacturing.
Q:What is the expected revenue mix for 2026, and how will it bifurcate between system revenue and consumable revenue?
A:System revenue is expected to be in the teens or high teens, with recurring revenue scaling linearly. System revenue will likely constitute 30-50% of overall revenue, with the rest coming from consumables.
Q:What were the FDA's questions regarding the MAGiC submission, and what is the status of the review?
A:The FDA's questions were comprehensive, covering preclinical testing, clinical data, biocompatibility, sterility, packaging, labeling, and technical testing. The company responded to these questions at the end of Q3 and feels good about the responses. The review is progressing as expected.
Q:Why was the Q4 guidance for disposables and service revenue adjusted?
A:The adjustment reflects the timing of FDA and CE mark approvals for MAGiC and MAGiC Sweep. While the ramp of MAGiC Sweep in the U.S. has been strong, the company is still in the early stages of adoption.
Q:How will the commercial organization expand over the next 12-24 months with the launch of GenesisX and new catheters?
A:The clinical team will grow to allow a one-to-one relationship between clinical reps and hospitals. The capital team may also expand by a handful of dedicated capital reps as GenesisX sales scale.
Q:What are the long-term opportunities for the disposables business?
A:The company is focusing on three main portfolios: MAGiC family of robotically steered ablation catheters, interventional guidewires and catheters for vascular navigation, and Map-iT manual diagnostic EP catheters. Continuous innovation is expected in these areas, with additional pipeline projects in development.
Q:Review of Unclear Management Responses
A:Management avoided providing a specific timeline for the full launch of GenesisX, stating it would likely occur in the earlier parts of next year but did not commit to a precise date. Additionally, while discussing the FDA's review of MAGiC, the responses were general and lacked detailed insights into the specific outstanding issues or timeline for approval.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI feature
APT adoption
CE catheter
CE month
CardioFocus PFA
Catheters disposable
EP field
EPs technology
Europe CE
Europe MAGiC
Europe product
FDA approval
Genesis order
MAGiC Sweep
MAGiC ablation
MAGiC catheter
Map catheter
Sweep density
SynX
adoption MAGiC
afternoon
agreement
call
catheter Europe
catheter interest
catheter robot
collaboration
date
disposable procedure
lab workflow
noncash charge
project
robot use
service
software
solution
stream
sweep
testing
workflow connectivity
STXS Transcript
Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript
Unknown5-12
The earnings call presents mixed signals: while there are promising developments like ramping up MAGiC catheter production and GenesisX system expansion, financial performance in Q1 2026 was weak with declining revenues and increased losses. The Q&A reveals confidence in future growth, yet lacks concrete timelines and details, which could cause investor hesitation. Given the absence of a market cap and the mixed sentiment, the stock price is likely to remain stable, resulting in a neutral prediction.
Stereotaxis, Inc. (STXS) Q4 2025 Earnings Call Transcript
Unknown3-9
The earnings call reveals mixed elements: a strong product pipeline with FDA approvals and optimistic future revenue growth, but current challenges include negative free cash flow, operating losses, and manufacturing issues. The Q&A highlights stable revenue from existing products and positive feedback on new launches, but also concerns about manufacturing constraints and management's vague responses on key issues. These factors balance each other out, leading to a neutral sentiment.
Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call Transcript
Unknown11-11
The earnings call presented mixed signals: while product development with GenesisX and new catheters is promising, financials show consistent losses and a negative cash flow. The Q&A reveals a cautious approach to new launches and regulatory approvals, indicating uncertainty. No strong catalysts like partnerships or guidance changes were mentioned. Therefore, the stock is likely to remain stable in the short term.
Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call Transcript
Unknown5-12
The earnings call presents mixed signals: while product development and business updates show promise, especially in Europe, financial performance is concerning with declining system revenue and increasing operating losses. The Q&A reveals positive reception of new products but highlights uncertainties in U.S. regulatory approvals and market adoption challenges. The lack of a share repurchase program and structural challenges further dampen sentiment. Overall, the mixed guidance and financials, coupled with regional uncertainties, suggest a neutral stock price movement.
STXS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
